NCT00396175已完成3 期
A Double-Blind, Placebo-Controlled, Multicenter Study To Examine the Effects of Finasteride 1 MG on Serum Prostate-Specific Antigen in Men With Androgenetic Alopecia
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 355
- 主要终点
- Serum Prostatic Specific Antigen (PSA) after 48 weeks of treatment
研究概览
简要总结
A clinical study to collect additional data in order to characterize the reduction in PSA with finasteride 1 mg, and its reversibility in men with androgenetic alopecia between the ages of 40 to 60 years.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 40 Years 至 60 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Serum Prostatic Specific Antigen (PSA) after 48 weeks of treatment
次要结局
- Reversibility of effects on Serum Prostatic Specific Antigen (PSA) after 24 weeks off drug
研究者
相似试验
已完成
1 期
A Multicentre, Randomised, Double-blind, Placebo-controlled Proof of Concept Study to Compare the Efficacy and Safety of r-hLIF (Emfilermin) for Improving Embryo Implantation Following in Vitro Fertilization (IVF) and Embryo Transfer (ET) in Women With Recurrent Implantation FailureInfertility Implantation FailureNCT00504608Merck KGaA, Darmstadt, Germany150
已完成
4 期
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1Pulmonary Disease, Chronic ObstructiveNCT01663987Boehringer Ingelheim79
已完成
4 期
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2Pulmonary Disease, Chronic ObstructiveNCT01662986Boehringer Ingelheim79
已完成
3 期
A Study to Evaluate the Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled on MonotherapyHypertensionNCT00327145Novartis894
终止
2 期
A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver CancerCarcinoma, HepatocellularNCT01911273Pfizer3